Inito has raised $29 million in its Series B round, led by Bertelsmann India Investments, bringing total funding to $45 million. The company plans to expand from fertility diagnostics into wider at-home hormone and health testing using AI-engineered antibodies. Inito’s technology aims to improve accuracy and access by moving beyond conventional diagnostic methods.